Novo Holdings, SR One and Catalys Pacific co-led the $205m Series A financing in Crystalys Therapeutics.

Novo Holdings, SR One, and Catalys Pacific, all venture capital firms, co-led the $205m Series A financing in Crystalys Therapeutics, a clinical-stage biotech company focused on gout therapies, with participation from Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, abrdn, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund.